Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ZVSA save search
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 7.38%
H: 2.6%
C: -3.23%
therapeutics diabetes potential
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 0.11%
H: 0.0%
C: -2.07%
business year update therapeutics financial results
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 7.64%
H: 21.41%
C: 1.07%
disease kidney cholesterol approval trial therapeutics diabetic
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
Published: 2024-03-14 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 3.71%
H: 1.23%
C: -1.37%
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 11.93%
H: 1.64%
C: -18.03%
obesity review therapeutics
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 1.64%
H: 17.44%
C: 0.05%
neurological therapeutics 100 potential
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 2.52%
H: 4.39%
C: 1.51%
review neurological therapeutics
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: -4.1%
H: 5.14%
C: 1.69%
ceo conference update key
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: -4.07%
H: 7.97%
C: -3.37%
children publication risk therapeutics diabetes insulin
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 4.07%
H: 1.56%
C: 1.55%
disease alzheimer’s therapeutics potential
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
Published: 2024-01-17 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 21.31%
H: 0.0%
C: -17.86%
breast cancer therapeutics
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
Published: 2024-01-10 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 2.74%
H: 0.0%
C: -1.89%
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 2.39%
H: 0.0%
C: -3.68%
research therapeutics initiated
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 2.28%
H: 8.88%
C: 2.0%
therapeutics
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
Published: 2023-12-18 (Crawled : 13:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 1.65%
H: 48.51%
C: 35.82%
week
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 10.48%
H: 7.4%
C: -11.99%
cholesterol trial therapeutics
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
Published: 2023-12-07 (Crawled : 17:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: -42.06%
H: 42.74%
C: -7.26%
disease kidney publication therapeutics diabetes diabetic
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
Published: 2023-12-07 (Crawled : 02:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: -42.06%
H: 42.74%
C: -7.26%
offering
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
Published: 2023-12-06 (Crawled : 12:30) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 33.63%
H: 4.49%
C: -26.2%
publication therapeutics
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
Published: 2023-11-30 (Crawled : 03:00) - globenewswire.com
ZVSA | $0.581 -7.19% -7.75% 280K
|
|
| O: 6.38%
H: 21.1%
C: -35.0%
authorized
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.